Temple University the Latest Academic Medical Center to Plan Ivermectin Trial: Does the Drug Inhibit SARS-CoV-2 Progression?

Temple University the Latest Academic Medical Center to Plan Ivermectin Trial: Does the Drug Inhibit SARS-CoV-2 Progression?

Temple University goes back to 1884, founded by Baptist Minister Russell Cornwell. Over a century later with over 40,000 students, the university prepares the largest body of professional practitioners in the State of Pennsylvania. The Lewis Katz School of Medicine has ranked as one of the ten most-sought-after medical schools in the United States. Temple University is now the latest academic medical center to plan an ivermectin clinical trial in the United States targeting SARS-CoV-2, the virus behind COVID-19. Can Temple prove to all that ivermectin can represent a low cost, available option to inhibit the progression of severe COVID-19 infections?

The Key Goal: Low Cost, Simple & Safe Inhibition of COVID-19

A premise in ivermectin research centers on the fact that most COVID-19 cases are mild to moderate; however, for some, the disease can progress to a far more dangerous and even deadly condition. Temple University reports that currently, 81% of COVID-19 patients are afflicted with mild to moderate disease, while 14% of patients may progress to a more severe state.

As is the case in low-and middle-income countries (LMICs), many physicians and researchers seek low-...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee